Glaucoma Physician

Home
Glaucoma Physician

Glaucoma Physician delivers timely information on the fast-evolving glaucoma space.

09/09/2026

📖 The September issue of Glaucoma Physician is here!

This month, leading experts explore some of the questions shaping glaucoma care today, from what to do when IOP rises after MIGS to predicting success after angle surgery and the evolving role of sustained drug delivery.

Inside the issue:
🔹 Is there still a role for SLT after MIGS?
🔹 Can we better predict which patients will benefit from angle-based surgery?
🔹 What have early adopters learned about procedural pharmaceuticals?
🔹 How could proposed Medicare coverage policies for iDose TR affect patient care?
🔹 What’s next for sustained drug delivery in glaucoma?

Plus, explore the latest glaucoma clinical trials, practical strategies for patient education, and more.

👉 Read the September issue: https://ow.ly/FcnW50ZJrtM

08/09/2026

🔄 Rethinking repeat SLT

Can a second SLT help patients stay off topical medications?

Kateki Vinod, MD, highlights evidence from the LiGHT trial showing that 67% of eyes undergoing repeat SLT maintained target IOP without additional treatment at 18 months.

👁️ Read her perspective and more expert insights on SLT: https://ow.ly/m6UC50ZF8s3

07/09/2026

💊 What’s next for sustained drug delivery in glaucoma?

The pipeline is moving beyond today’s implants, exploring everything from longer-lasting reservoirs and biodegradable platforms to drug delivery incorporated into cataract surgery.

But extending treatment is only part of the challenge. Ciera D. Johnson, BS, Rachel Chapman, Samantha Goldburg, MD, and Mary Qiu, MD, explore the questions around repeatability, safety, clinical integration and finding the right approach for each patient.

🔗 Explore the next generation of sustained drug delivery: https://ow.ly/nwzP50ZKmyN

03/09/2026

💡 Rethinking what we know about SLT

Lauren S. Blieden, MD, Baylor College of Medicine, shares how evidence from the LiGHT trial changed her approach to repeat selective laser trabeculoplasty, including reconsidering what to do when a patient doesn’t respond the first time.

Could an early repeat SLT achieve the response you were looking for?

🔗 Discover this and more expert insights in Things You Didn’t Know About SLT: https://ow.ly/4Gwu50ZF8kg

02/09/2026

💡 Dispelling myths about SLT

In this article, John Berdahl, MD (Vance Thompson Vision) highlights a surprising gap in glaucoma care.

🗣️ “Nearly all ophthalmologists say they would choose SLT first if it were their own eye—yet most report using it as initial therapy in only about 10% of patients.”

Why the disconnect between physician preference and real-world practice?

From: Things You Didn’t Know About SLT 👉 https://ow.ly/pLis50Ypy11

01/09/2026

💧 The FDA has accepted Kowa’s NDA for K-911, a once-daily eye drop for lowering IOP in patients with open-angle glaucoma or ocular hypertension.

A PDUFA target action date has been set for April 30, 2027.

🔗 Read more: https://ow.ly/27YT50ZHBPA

28/08/2026

How can clinicians turn growing volumes of glaucoma data into better patient outcomes?

In this article, Lama A. Al-Aswad, MD, MPH, and Almiqdad Saeed, MD, explore how decision intelligence can support earlier diagnosis, personalized treatment strategies, and more informed clinical decision-making.

Read more: https://ow.ly/aocU50Z7UIa

27/08/2026

👁️ A new way to bring ophthalmic data together.

The FDA has cleared ZEISS Clinic 360, a cloud-based platform designed to give clinicians a unified view of diagnostic and patient data while supporting disease monitoring and clinical workflows.

🔗 Read more: https://ow.ly/x0JP50ZFvhI

26/08/2026

🧬 Could gene therapy help protect the optic nerve in glaucoma?

Astellas has launched a phase 1/2 trial of ASP2767, a first-in-human gene therapy targeting optic nerve damage in open-angle glaucoma.

🔗 Read more: https://ow.ly/L68A50ZFv5S

19/08/2026

🌙 Could nighttime IOP management be entering a new phase?

CMS has finalized 2026 Medicare pricing for Balance Ophthalmics’ Fsyx Ocular Pressure Adjusting Pump and goggles, with rates taking effect October 1.

The prescription-only system uses pressure-modulating goggles and a pump to apply negative pressure to the eyes during sleep. Balance Ophthalmics expects broader commercialization to begin in Q4 2026.

👁️ Could nocturnal IOP lowering become a bigger part of glaucoma management?

🔗 Read the latest: https://ow.ly/z1EK50ZBnP9

Address

321 Norristown Road

19002

Telephone

215-628-6550

Website

http://www.glaucomaphysician.net/

Alerts

Be the first to know and let us send you an email when Glaucoma Physician posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Media Company?

Country:

City: